Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 79% Improvement Relative Risk Vitamin D  Karimpour-Razkenari et al.  LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 478 patients in Iran (February - May 2020) Lower mortality with vitamin D (p=0.000092) c19early.org Karimpour-Razkenari et al., J. Pharmac.., Oct 2022 Favors vitamin D Favors control

Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19

Karimpour-Razkenari et al., Journal of Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 478 moderate to severe hospitalized patients in Iran, showing lower mortality with vitamin D treatment.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 39% [26‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 97th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).
29 studies are RCTs, which show efficacy with p=0.0000024.
Study covers aspirin and vitamin D.
risk of death, 79.0% lower, RR 0.21, p < 0.001, treatment 10 of 124 (8.1%), control 93 of 329 (28.3%), NNT 4.9, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karimpour-Razkenari et al., 3 Oct 2022, retrospective, Iran, peer-reviewed, median age 58.5, 9 authors, study period 23 February, 2020 - 23 May, 2020, dosage not specified. Contact: ghazaeianm@gmail.com.
This PaperVitamin DAll
Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19
Dr Monireh Ghazaeian, Elahe Karimpour-Razkenari, Javad Boskabadi, Hamidreza Samaee, Hanieh Azizi, Fatemeh Esfandiari, Seyed Abdollah Mousavi, Sahar Fallah, Sekineh Talebi
The coronavirus disease 2019 (COVID-19) is highly contagious and has turned into a global health problem. In this study, we investigated the role of clinical and laboratory characteristics along with administered therapeutic agents in patients with COVID-19, and identified some effective factors on the mortality of these individuals. Methods: In this retrospective study, we evaluated the data from all the hospitalized patients who had been diagnosed with COVID-19 between February 23 and May 23, 2020. The data were obtained from medical records. Additionally, a checklist was used to record demographic, clinical, laboratory, imaging, and treatment data for each patient. Results: Totally, 478 patients were involved in this study, and their median age was 58.5 years. Of these, 53.3% patients were male. The most common pre-existing underlying disease was hypertension (37.9%), and the mortality group had significantly more comorbidities (85.4%). Higher neutrophil lymphocyte ratio (NLR), lymphopenia, and reduced hemoglobin were more frequent in the mortality group (p < 0.001). Similarly, the need to be admitted to the intensive care unit was significantly greater in the mortality group (p<0.001). The most frequently administered therapeutic regimens included hydroxychloroquine and lopinavir/ritonavir, which did not have any correlation with survival outcome. Conclusion: Older age, opioid addiction, cardiovascular disease, kidney disease, baseline NLR and hemoglobin, and ICU admission were independently associated with COVID-19 mortality. On the other hand, hydroxychloroquine and lopinavir/ritonavir indicated no beneficial effects on patients' outcome.
September 2022;10(3) Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens
References
Adham, Habibzadeh, Ghobadi, Abbasi-Ghahramanloo, Moradi-Asl, Epidemiological Characteristics and Mortality Risk Factors among COVID-19 Patients in Ardabil, Northwest of Iran, BMC Emerg Med
Amrein, Schnedl, Holl, Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial, JAMA
Anai, Akaike, Iwagoe, Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia, Respir Investig
Burton, Fort, Seoane, Hospitalization and mortality among black patients and white patients with Covid-19, New Engl J Med
Carpagnano, Lecce, Quaranta, Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19, J Endocrinol Invest
Cfd, Prevention, Coronavirus disease
Cfd, Prevention, Coronavirus disease 2019 (COVID-19): people who are at increased risk for severe illness
Cfd, Prevention, Health equity considerations and racial and ethnic minority groups
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Dubey, Ghosh, Chatterjee, Biswas, Chatterjee et al., COVID-19 and addiction, Diabetes Metab Syndr
Estebanez, Ramirez-Olivencia, Mata, Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study
Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Ther Adv Respir Dis
Khwaja, KDIGO clinical practice guidelines for acute kidney injury, Nephron Clin Pract
Lescot, Karvellas, Beaussier, Magder, Riou, Acquired liver injury in the intensive care unit, Anesthesiology
Mao, Wang, Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China, JAMA Neurol
Mardani, Vasmehjani, Zali, Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study, Arch Acad Emerg Med
Mcmichael, Clark, Pogosjans, COVID-19 in a long-term care facility-King County, Washington, MMWR Morb Mortal Wkly Rep
Mirjalili, Dastgheib, Shaker, Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis, J Diabetes Metab Disord
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Organization, Anaemia -WHO | World Health Organization
Palaiodimos, Kokkinidis, Li, Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, Metabolism
Rahmani, Davoudi-Monfared, Nourian, Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir, DARU
Ren, Wang, Wu, Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study, Chin Med J (Engl)
Rouhani, Karimpour-Razkenari, Forutan, Ghazaeian, Salehifar et al., Efficacy and Safety of Interferon Beta-1b in the Management of Patients with COVID-19: A Prospective, Open-Label, Non-Randomized Trial, J Pharm Care
Sobhani, Aryan, Kalantari, Soltani, Malek et al., Association between Clinical Characteristics and Laboratory Findings with Outcome of Hospitalized COVID-19 Patients: A Report from Northeast Iran, I Interdiscip Perspect Infect Dis
Stokes, Zambrano, Anderson, Coronavirus disease 2019 case surveillance-United States, MMWR Morb Mortal Wkly Rep
Taneri, Gómez-Ochoa, Llanaj, Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis, Europ J Epidemiol
Terpos, Ntanasis-Stathopoulos, Elalamy, Hematological findings and complications of COVID-19, Am J Hematol
Wj, Zy, Hu, Clinical characteristics of coronavirus disease 2019 in China, New Engl J Med
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
{ 'DOI': '10.18502/jpc.v10i3.10790', 'ISSN': ['2322-4509', '2322-4630'], 'URL': 'http://dx.doi.org/10.18502/jpc.v10i3.10790', 'abstract': '<jats:p>Background: The coronavirus disease 2019 (COVID-19) is highly contagious and has ' 'turned into a global health problem.\xa0 In this study, we investigated the role of clinical ' 'and laboratory characteristics along with administered therapeutic agents in patients with ' 'COVID-19, and identified some effective factors on the mortality of these individuals.&#x0D;\n' 'Methods: In this retrospective study, we evaluated the data from all the hospitalized ' 'patients who had been diagnosed with COVID-19 between February 23 and May 23, 2020. The data ' 'were obtained from medical records. Additionally, a checklist was used to record demographic, ' 'clinical, laboratory, imaging, and treatment data for each patient.&#x0D;\n' 'Results: Totally, 478 patients were involved in this study, and their median age was 58.5 ' 'years. Of these, 53.3% patients were male. The most common pre-existing underlying disease ' 'was hypertension (37.9%), and the mortality group had significantly more comorbidities ' '(85.4%).\xa0 Higher neutrophil lymphocyte ratio (NLR), lymphopenia, and reduced hemoglobin ' 'were more frequent in the mortality group (p &lt; 0.001).\xa0 Similarly, the need to be ' 'admitted to the intensive care unit was significantly greater in the mortality group ' '(p&lt;0.001). The most frequently administered therapeutic regimens included ' 'hydroxychloroquine and lopinavir/ritonavir, which did not have any correlation with survival ' 'outcome.&#x0D;\n' 'Conclusion: Older age, opioid addiction, cardiovascular disease, kidney disease, baseline NLR ' 'and hemoglobin, and ICU admission were independently associated with COVID-19 mortality. On ' 'the other hand, hydroxychloroquine and lopinavir/ritonavir indicated no beneficial effects on ' 'patients’ outcome.</jats:p>', 'author': [ {'affiliation': [], 'family': 'Karimpour-razkenari', 'given': 'Elahe', 'sequence': 'first'}, {'affiliation': [], 'family': 'Boskabadi', 'given': 'Javad', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ghazaeian', 'given': 'Monireh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Samaee', 'given': 'Hamidreza', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Azizi', 'given': 'Hanieh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Esfandiari', 'given': 'Fatemeh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mousavi', 'given': 'Seyed Abdollah', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fallah', 'given': 'Sahar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Talebi', 'given': 'Sekineh', 'sequence': 'additional'}], 'container-title': 'Journal of Pharmaceutical Care', 'container-title-short': 'jpc', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 10, 8]], 'date-time': '2022-10-08T08:19:24Z', 'timestamp': 1665217164000}, 'deposited': { 'date-parts': [[2022, 10, 8]], 'date-time': '2022-10-08T08:19:38Z', 'timestamp': 1665217178000}, 'indexed': {'date-parts': [[2022, 10, 8]], 'date-time': '2022-10-08T08:45:10Z', 'timestamp': 1665218710832}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 10, 3]]}, 'member': '7770', 'original-title': [], 'prefix': '10.18502', 'published': {'date-parts': [[2022, 10, 3]]}, 'published-online': {'date-parts': [[2022, 10, 3]]}, 'publisher': 'Knowledge E DMCC', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://publish.kne-publishing.com/index.php/JPC/article/view/10790'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'General Earth and Planetary Sciences', 'Water Science and Technology', 'Geography, Planning and Development'], 'subtitle': [], 'title': 'Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in ' 'Hospitalized Patients with Severe COVID-19', 'type': 'journal-article'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit